Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;74(9):508-519.
doi: 10.1111/pin.13466. Epub 2024 Jul 17.

Digital whole-slide imaging of changes in amyloid after peripheral blood stem cell transplantation in patients with amyloid light-chain amyloidosis

Kei Kono  1   2   3 , Naoki Sawa  3   4 , Atsushi Wake  5 , Yukako Shintani-Domoto  6 , Takeshi Fujii  1 , Yutaka Takazawa  1 , Yoshifumi Ubara  3   4 , Kenichi Ohashi  1   2
Affiliations

Digital whole-slide imaging of changes in amyloid after peripheral blood stem cell transplantation in patients with amyloid light-chain amyloidosis

Kei Kono et al. Pathol Int. 2024 Sep.

Abstract

Peripheral blood stem cell transplantation (PBSCT) has made amyloid light-chain (AL) amyloidosis treatable. After PBSCT, hematological complete remission (HCR) can be achieved, leading to improved renal prognosis. The purpose of this study was to evaluate whether whole slide imaging of biopsy samples shows a post-treatment reduction in amyloid deposits in patients with AL amyloidosis. Patients were divided into three groups: Group A (n = 8), not eligible for PBSCT and treated with other therapies; Group B (n = 11), treated with PBSCT and achieved HCR; and Group C (n = 5), treated with PBSCT but did not achieve HCR. Clinical findings and amyloid deposition in glomeruli, interstitium, and blood vessels were compared before and after treatment using digital whole-slide imaging. Proteinuria and hypoalbuminemia improved more in Group B than in the other groups, and in Group B, amyloid deposition improved more in the glomeruli than in the interstitium and blood vessels. The long-term renal and survival prognosis was better in Group B than in the other groups. PBSCT can be expected to improve long-term clinical and renal histological prognosis in patients with AL amyloidosis who achieve HCR. Amyloid disappearance from renal tissue may take a long time even after clinical HCR.

Keywords: AL amyloidosis; hematological complete remission; peripheral blood stem cell transplantation; whole‐slide imaging.

PubMed Disclaimer

References

REFERENCES

    1. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–1207.
    1. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276–4282.
    1. Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with vad and subsequent high‐dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42:72–77.
    1. Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high‐dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid. 2004;11:245–256.
    1. Hoshino J, Ubara Y, Sawa N, Sumida K, Hiramatsu R, Hasegawa E, et al. How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high‐dose melphalan, low‐dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis. Clin Exp Nephrol. 2011;15:486–492.

LinkOut - more resources